Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA.
Headache
; 62(10): 1322-1328, 2022 11.
Article
in En
| MEDLINE
| ID: mdl-36437599
ABSTRACT
BACKGROUND:
The effectiveness of onabotulinumtoxinA (BTX-A) has been established in primary trigeminal neuralgia (TN). However, to the best of our knowledge, the efficacy of BTX-A in secondary TN has not yet been studied.OBJECTIVE:
This study aimed to investigate the efficacy of BTX-A treatment in patients with multiple sclerosis-related trigeminal neuralgia (TN-MS) and compare the efficacy of BTX-A treatment between patients with primary trigeminal neuralgia (TN-P) and patients with TN-MS.METHODS:
This was a retrospective medical record-review study. Demographic and clinical features and severity and frequency of pain before and 2 weeks after the BTX-A administration were extracted from the patient files. BTX-A was injected into the painful area subcutaneously and/or submucosally. BTX-A injections were performed by the same physician using the same methods. A reduction in severity and/or frequency of pain ≥50% was considered therapeutic efficacy.RESULTS:
Fifty-three patients were included in this study. We classified 22 (42%) as TN-P and 31 (58%) as TN-MS. Treatment with BTX-A was effective in 16 of 31 (52%) patients with TN-MS and 10 of 22 (45%) with TN-P. BTX-A treatment was less effective in patients with a history of interventional treatments and more effective in patients with concomitant continuous pain (p = 0.007; odds ratio [OR] 0.020-0.53 and p = 0.047; OR 0.046-0.98, respectively).CONCLUSION:
The BTX-A treatment was found to be effective in at least half of our cohort with TN-MS. Concomitant continuous pain and history of interventional treatments to the trigeminal nerve or ganglion might be predictive factors for the efficacy of BTX-A treatment.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Trigeminal Neuralgia
/
Multiple Sclerosis
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Headache
Year:
2022
Document type:
Article
Affiliation country:
Turkey